EpiCept Announces Resignation of Board Member

EpiCept Announces Resignation of Board Member 

TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News: 

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that John
F. Bedard has resigned from the Company's Board of Directors, effective February
3, 2009, solely because of a family health reason. Mr. Bedard was a member of
EpiCept's Board since January 2006. 

“On Behalf of EpiCept and its shareholders, I would like to thank John for his
many contributions to the Company and its Board of Directors. We completely
understand that he needs to devote his time and energies towards his family. We
will look to fill this vacancy as soon as possible,” remarked Jack Talley,
President and CEO of EpiCept. 

About EpiCept Corporation 

EpiCept is focused on unmet needs in the treatment of cancer and pain. The
Company's broad portfolio of pharmaceutical product candidates includes
Ceplene®, a cytokine immunomodulator that recently received marketing
authorization in Europe for the remission maintenance of AML patients, and
several pain therapies in clinical development. Two oncology drug candidates
currently in clinical development that were discovered using in-house technology
have also been shown to act as vascular disruption agents in a variety of solid
tumors. 

Forward-Looking Statements 

This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risks associated with the adequacy of our existing cash resources,
our need to raise additional financing to continue to meet our capital needs and
our ability to continue as a going concern, the risks associated with our
ability to continue to meet our obligations under our existing debt agreements
or that we may default on our loans or that our lenders may declare us in
default or that our secured lender would seek to sell our assets, the risk that
our securities may be delisted by The Nasdaq Capital Market or the OMX Nordic
Exchange and that any appeal of the delisting determination may not be
successful, the risk that Ceplene® will not receive regulatory approval or
marketing authorization in the U.S. or Canada, the risk that Ceplene® will not
be launched in Europe in the first half of 2009 or achieve significant
commercial success, the risk that we are unable to find a suitable marketing
partner for Ceplene® on attractive terms, a timely basis or at all, the risk
that any required post-approval clinical study will not be successful, the risk
that we will not be able to maintain its final regulatory approval or marketing
authorization, the risk that Myriad's development of Azixa™ will not be
successful, the risk that Azixa™ will not receive regulatory approval or achieve
significant commercial success, the risk that we will not receive any
significant payments under our agreement with Myriad, the risk that the
development of our other apoptosis product candidates will not be successful,
the risk that we will not be able to find a buyer for our ASAP technology, the
risk that clinical trials for NP-1 or EPC-2407 will not be successful, the risk
that NP-1 or EPC-2407 will not receive regulatory approval or achieve
significant commercial success, the risk that we will not be able to find a
partner to help conduct the Phase III trials for NP-1 on attractive terms or a
timely basis at all, the risk that our other product candidates that appeared
promising in early research and clinical trials do not demonstrate safety and/or
efficacy in larger-scale or later stage clinical trials, the risk that we will
not obtain approval to market any of our other product candidates, the risks
associated with our dependence upon key personnel, the risks associated with
reliance on collaborative partners and others for further clinical trials,
development, manufacturing and commercialization of our product candidates; the
cost, delays and uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our history of
operating losses since our inception; the highly competitive nature of our
business; risks associated with litigation; and risks associated with our
ability to protect our intellectual property. These factors and other material
risks are more fully discussed in our periodic reports, including its reports on
Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange
Commission. You are urged to carefully review and consider the disclosures found
in our filings, which are available at www.sec.gov or at www.epicept.com. You
are cautioned not to place undue reliance on any forward-looking statements, any
of which could turn out to be wrong due to inaccurate assumptions, unknown risks
or uncertainties or other risk factors. 

EPCT-GEN 

*Azixa is a registered trademark of Myriad Genetics, Inc. 


Contacts
EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com